• Gepotidacin Workflows for Resistance Research

  2026-10-01

  Gepotidacin, also known as GSK2140944, enables mechanistic antibacterial research across enzyme assays, susceptibility testing, and resistance-focused isolate profiling. This guide translates its distinctive topoisomerase activity and clinical study design into practical workflows, controls, and troubleshooting strategies.

• Ceftazidime: A Transmission-Aware Assay Framework

  2026-10-01

  Ceftazidime can do more than generate a susceptibility result. This transmission-aware framework connects β-lactam activity, resistance-gene localization, plasmid mobility, and respiratory infection research to improve interpretation of Gram-negative bacterial infection studies.

• Ertapenem Sodium Salt for Resistance Research

  2026-09-30

  Use Ertapenem sodium salt to connect PBP biology with broth microdilution, carbapenemase surveillance, plasmid localization, and transfer assays. This practical framework emphasizes reproducible controls, phenotype–genotype interpretation, and troubleshooting for antibiotic resistance research.

• Polymyxin B in CREC Assay Design

  2026-09-30

  Polymyxin B sulfate can do more than produce a susceptibility readout: it can help connect membrane activity, carbapenemase-gene mobility, and host-response measurements. This article presents an evidence-aware assay framework for Gram-negative bacterial infection research.

• CAPE Protects Against C. difficile by Targeting TcdB

  2026-09-29

  Guo and colleagues identify caffeic acid phenethyl ester (CAPE) as a toxin-directed candidate against Clostridioides difficile infection, combining cell-based screening with toxin mechanistic assays and a murine infection model. The study links TcdB inhibition with changes in disease severity, gut microbiota, and metabolites, while also defining important limitations for therapeutic translation.

• Tyrothricin Workflows for Membrane-Disruption Studies

  2026-09-29

  Build reproducible bacterial, fungal, and selected viral membrane-disruption assays with Tyrothricin, a practical peptide antibiotic mixture for mechanism-focused research. The workflow emphasizes concentration scouting, orthogonal readouts, mammalian-cell counter-screens, and storage practices that help separate antimicrobial activity from assay artifacts.

• CAPE Protects Against C. difficile by Toxin Inhibition

  2026-09-28

  The reference study identifies caffeic acid phenethyl ester (CAPE) as an inhibitor of the C. difficile toxin TcdB and links its activity to both toxin suppression and gut microbiota changes. Its findings support CAPE as an anti-virulence lead, while the moderate animal-model effects and unresolved binding evidence define important translational limits.

• Tobramycin in Cell Assays: Reliable Use and Limits

  2026-09-28

  Learn when Tobramycin (SKU B1856) can support microbiology or infection-model workflows—and why it should not be treated as a cell-viability reagent. This evidence-led guide covers assay compatibility, formulation, resistance data, and practical product-selection criteria.

• Midecamycin’s In Vitro Spectrum: A 1983 Study

  2026-09-27

  Harold C. Neu’s 1983 study mapped the in vitro activity of midecamycin across clinical bacterial isolates, finding useful inhibition of many Gram-positive organisms but little activity against Enterobacteriaceae or Pseudomonas. Its comparison with erythromycin also showed that midecamycin did not overcome erythromycin resistance, a result that limits how broadly its spectrum can be interpreted.

• Faropenem Sodium and Renal Transport: Assay Insight

  2026-09-26

  Faropenem sodium is best understood not only as a penem antibiotic, but also as a transporter substrate with implications for experimental design. Explore how human NPT1 findings can inform renal transport assays without being mistaken for evidence of bacterial potency or clinical exposure.

• Pentoxifylline in Sperm Motility Research

  2026-09-25

  Explore how Pentoxifylline, a phosphodiesterase inhibitor, is used to stimulate sperm movement in assisted reproduction research. This evidence-focused guide translates reported in vitro findings into practical assay decisions while clarifying what motility results can—and cannot—say about clinical outcomes.

• Cefoperazone: Interpreting Activity Across Assays

  2026-09-25

  Cefoperazone sodium salt offers a useful model for studying how β-lactamase stability, assay design, and infection-site exposure shape antibacterial findings. This article separates what comparative in vitro studies can show from what researchers must test in their own bacterial and biliary models.

• Penicillin G Sodium: Bench Workflows & Troubleshooting

  2026-09-24

  Build a more interpretable antimicrobial workflow with Penicillin G Sodium by pairing fresh-solution handling with controlled susceptibility testing and appropriate resistance controls. A separate intestinal-barrier study offers useful assay-design lessons—but not evidence that this antibiotic protects epithelial barriers.

• Ampicillin Sodium: Assays, Selection & Troubleshooting

  2026-09-24

  Use Ampicillin sodium to investigate bacterial cell wall inhibition, compare antibacterial responses, or maintain ampicillin-selectable expression constructs. This guide connects assay design and practical controls with a classic recombinant-protein workflow, while clarifying where those applications should—and should not—be interpreted together.

• Sodium dicloxacillin monohydrate in MSSA assays

  2026-09-23

  Build paired extracellular and intracellular MSSA assays to see where dicloxacillin activity changes—and why broth MIC alone may not predict the full response. This guide turns published time-kill and PK/PD findings into practical concentration, pH, and sampling choices for research workflows.

8021 records 1/535 page Next 12345 下5页 Last page